Abstract | OBJECTIVE: METHODS: A Markov model estimated the cost-effectiveness of dabigatran etexilate versus warfarin, aspirin or no therapy. Two patient cohorts with AF (starting age of <80 and ≥80 years) were considered separately, in line with the UK labelled indication. Modelled outcomes over a lifetime horizon included clinical events, quality-adjusted life years (QALYs), total costs and incremental cost-effectiveness ratios (ICERs). RESULTS: CONCLUSIONS: This economic evaluation suggests that the use of dabigatran etexilate as a first-line treatment for the prevention of stroke and systemic embolism is likely to be cost-effective in eligible UK patients with AF.
|
Authors | Anuraag R Kansal, Sonja V Sorensen, Ray Gani, Paul Robinson, Feng Pan, Jonathan M Plumb, Martin R Cowie |
Journal | Heart (British Cardiac Society)
(Heart)
Vol. 98
Issue 7
Pg. 573-8
(Apr 2012)
ISSN: 1468-201X [Electronic] England |
PMID | 22422743
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antithrombin Proteins
- Benzimidazoles
- Pyridines
- Dabigatran
|
Topics |
- Aged, 80 and over
- Antithrombin Proteins
- Atrial Fibrillation
(complications, economics)
- Benzimidazoles
(economics, therapeutic use)
- Cost-Benefit Analysis
- Dabigatran
- Drug Costs
- Embolism
(economics, etiology, prevention & control)
- Female
- Follow-Up Studies
- Humans
- Male
- Models, Economic
- Pyridines
(economics, therapeutic use)
- Stroke
(economics, etiology, prevention & control)
- United Kingdom
|